Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments

BACKGROUND: Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in general, its efficacy in patients who did...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuruppu, Dulanji K., Tobin, Joshua, Dong, Yan, Aurora, Sheena K., Yunes-Medina, Laura, Green, A. Laine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063415/
https://www.ncbi.nlm.nih.gov/pubmed/33892641
http://dx.doi.org/10.1186/s12883-021-02196-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063415/
https://www.ncbi.nlm.nih.gov/pubmed/33892641
http://dx.doi.org/10.1186/s12883-021-02196-7

Ejemplares similares